BRPI1013904A2 - método e composição para tratar cetoacidose diabética - Google Patents

método e composição para tratar cetoacidose diabética

Info

Publication number
BRPI1013904A2
BRPI1013904A2 BRPI1013904A BRPI1013904A BRPI1013904A2 BR PI1013904 A2 BRPI1013904 A2 BR PI1013904A2 BR PI1013904 A BRPI1013904 A BR PI1013904A BR PI1013904 A BRPI1013904 A BR PI1013904A BR PI1013904 A2 BRPI1013904 A2 BR PI1013904A2
Authority
BR
Brazil
Prior art keywords
composition
treating diabetic
diabetic ketoacidosis
ketoacidosis
treating
Prior art date
Application number
BRPI1013904A
Other languages
English (en)
Inventor
Anil Gulati
Original Assignee
Univ Midwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Midwestern filed Critical Univ Midwestern
Publication of BRPI1013904A2 publication Critical patent/BRPI1013904A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1013904A 2009-04-30 2010-04-30 método e composição para tratar cetoacidose diabética BRPI1013904A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17428309P 2009-04-30 2009-04-30
PCT/US2010/033083 WO2010127197A2 (en) 2009-04-30 2010-04-30 Method and composition for treating diabetic ketoacidosis

Publications (1)

Publication Number Publication Date
BRPI1013904A2 true BRPI1013904A2 (pt) 2016-07-19

Family

ID=43032791

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013904A BRPI1013904A2 (pt) 2009-04-30 2010-04-30 método e composição para tratar cetoacidose diabética

Country Status (10)

Country Link
US (1) US8980874B2 (pt)
EP (1) EP2424530B1 (pt)
JP (1) JP5536198B2 (pt)
CN (1) CN102548553B (pt)
AU (1) AU2010242930B2 (pt)
BR (1) BRPI1013904A2 (pt)
CA (1) CA2759795C (pt)
ES (1) ES2562957T3 (pt)
PL (1) PL2424530T3 (pt)
WO (1) WO2010127197A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5498571B2 (ja) 2009-04-30 2014-05-21 ミッドウェスタン ユニバーシティ センタキンを用いた新規の治療方法
KR20210003831A (ko) * 2018-04-20 2021-01-12 버지니아 테크 인터렉추얼 프라퍼티스, 인크. 미토콘드리아 언커플러로서 유용한 아미노피라진 및 관련 화합물
MX2022005063A (es) 2019-10-30 2022-08-04 Perfuse Therapeutics Inc Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
WO2021118826A1 (en) * 2019-12-12 2021-06-17 Daljit Dhanoa Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides
KR20220143685A (ko) 2020-02-06 2022-10-25 퍼퓨즈 세라퓨틱스, 인크. 안질환의 치료를 위한 조성물
EP4117685A4 (en) * 2020-03-11 2024-03-20 Amorphical Ltd. AMORPHOUS CALCIUM CARBONATE FOR THE TREATMENT OF ACIDOSIS
MX2023012723A (es) 2021-04-30 2024-02-08 Perfuse Therapeutics Inc Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares.
AU2022264438A1 (en) * 2021-04-30 2023-11-23 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922681A (en) 1992-09-14 1999-07-13 Warner-Lambert Company Endothelin antagonists
WO2008043102A2 (en) 2006-10-06 2008-04-10 Transition Therapeutics Inc. Vasoactive intestinal polypeptide compositions
US20070293429A1 (en) * 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
EP2545920A1 (en) * 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes

Also Published As

Publication number Publication date
WO2010127197A3 (en) 2011-03-31
JP5536198B2 (ja) 2014-07-02
PL2424530T3 (pl) 2016-07-29
CN102548553A (zh) 2012-07-04
EP2424530A2 (en) 2012-03-07
US20120070513A1 (en) 2012-03-22
EP2424530B1 (en) 2015-12-16
JP2012525436A (ja) 2012-10-22
AU2010242930B2 (en) 2015-10-08
WO2010127197A2 (en) 2010-11-04
AU2010242930A1 (en) 2011-11-17
EP2424530A4 (en) 2012-09-12
CN102548553B (zh) 2016-07-13
CA2759795A1 (en) 2010-11-04
US8980874B2 (en) 2015-03-17
ES2562957T3 (es) 2016-03-09
CA2759795C (en) 2016-11-29

Similar Documents

Publication Publication Date Title
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BR112014014234A2 (pt) composição não colorante para tratar as fibras queratínicas e método para tratar as fibras queratínicas
BRPI1013878A2 (pt) método para tratar distúrbios metabólicos, e, composto
BR112012028514A2 (pt) composição para o tratamento da água residual e processo para o tratamento de água residual
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI0920326A2 (pt) composição e método para tratamento da síndrome do olho ressecado
BRPI1007561A2 (pt) método para revitalizar uma composição contendo betume, e, composição
BR112013019732A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI1008617A2 (pt) método e aparelho para lipoaspiração
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI1013361A2 (pt) método para evitar e tratar hipermeabilidade.
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BR112013004456A2 (pt) composição para tratamento de planta, e, método para o tratamento de plantas
BRPI0921959A2 (pt) métodos e composições para remoção de tatuagem
BRPI1006238A2 (pt) método para o tratamento pesticida de plantações e composição
BRPI0917496A2 (pt) metodo para realizacao de adaptacao de conteudos e servidor de adaptacao de conteudos
BRPI1013927A2 (pt) métodos e composições para o tratamento de lúpus
BRPI1008484A2 (pt) codificador, decodificador e método para os mesmos
BRPI1008326A2 (pt) Composições e métodos para controlar nanatódeos
BRPI0910406A2 (pt) equipamento e métodos para otmimização de tranporte para entrega de conteúdo widget
BR112012006437A2 (pt) composições e métodos para tratamento do diabetes e outros distúrbios
BRPI0923534A2 (pt) composição e método para tratamento de doenças de pele

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 16A ANUIDADE.